Introduction: Who Should Undergo Diagnostics

If you notice any changes in your breasts, it’s important to seek medical evaluation promptly. Common warning signs include a new lump or hardened area in or near your breast or armpit that doesn’t change with your menstrual cycle, changes in your breast’s size or shape, or skin changes affecting your breast or nipple. These skin changes might appear as dimpled, puckered, scaly, itchy, or discolored skin that looks reddish, purple, or unusually dark. Other concerning signs include nipple discharge that is bloody or clear, or a nipple that pulls inward.^[1]

It’s crucial to remember that breast cancer doesn’t always cause changes you can see or feel in the early stages. Many of these symptoms can also occur with noncancerous conditions, which is why professional medical assessment is essential. This is also why regular breast cancer screenings are so important, even when you feel perfectly healthy and notice no unusual changes.^[1]

Women who have certain risk factors should be especially vigilant about seeking diagnostic evaluation. These risk factors include having inherited genetic mutations like BRCA1 or BRCA2, which increase overall breast cancer risk. A personal history of breast cancer or having close biological relatives with breast cancer, such as a parent, sibling, or child, also increases your risk. Long-term exposure to high levels of estrogen or progesterone, such as getting your first period at an early age or starting menopause late, increases lifetime exposure to these hormones and may raise risk. Some forms of hormone therapy can also increase your risk.^[1]

Classic Diagnostic Methods for Identifying the Disease

When you present with symptoms or screening detects a breast abnormality, several diagnostic steps will follow to determine whether you have breast cancer and to identify its specific characteristics. The diagnostic process begins with clinical staging, which documents tumor size, lymph node involvement, and whether cancer has spread to other parts of the body. This staging uses a combination of clinical examinations and imaging studies to get a complete picture of the disease.^[5]

The most critical step in diagnosis is obtaining a tissue biopsy of the suspicious area. A biopsy involves removing a small sample of tissue from your breast so it can be examined under a microscope by specialized doctors called pathologists. This tissue sample provides the definitive answer about whether cancer is present and, if so, what type it is. The biopsy can be performed in several ways depending on the location and size of the abnormality, but all methods aim to collect enough tissue for thorough analysis.^[5]

Once cancer tissue is obtained through biopsy or surgery, standard pathological evaluation is carried out following guidelines from organizations like the College of American Pathologists. This evaluation examines multiple features of the cancer cells, including their appearance and behavior. For all invasive breast cancers, the laboratory will test for three key markers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2, commonly called HER2.^[2][5]

Understanding your hormone receptor status is a fundamental part of breast cancer diagnosis. A pathologist determines this by testing the tumor tissue removed during biopsy. Breast cancers are considered ER-positive if at least 1% of cells stain positive for estrogen receptor, and PR-positive if at least 1% of cells show progesterone receptor staining. When both tests are negative, meaning the cancer has few or no hormone receptors, the cancer is classified as hormone receptor negative.^[5][3]

Testing for HER2 status is equally important and is performed on all invasive breast cancers. Breast tissue samples are sent to a pathologist who examines several features, including HER2 levels. This protein, when present in excessive amounts, promotes cancer growth. Around 15 to 20% of all breast cancer cases are HER2 positive, meaning the cancer cells produce excessive amounts of the HER2 protein. These cancers can be more aggressive than some HER2 negative cancers but respond well to targeted treatments.^[2][10]

To measure HER2 levels, laboratories typically use a test called immunohistochemistry, or IHC. This involves a special staining process performed on the breast cancer tissue sample. The results are reported as a score ranging from 0 to 3+. A score of 0 or 1+ means the breast cancer is HER2-negative. A score of 3+ means the cancer is HER2-positive. If the result is 2+, which is considered borderline, the sample should be retested using more specialized techniques to determine whether it is HER2-positive, HER2-low, or HER2-negative.^[18]

In some cases, additional imaging tests may be needed to complete the diagnostic picture. These might include mammography, ultrasound, or magnetic resonance imaging (MRI) to better visualize the tumor and surrounding tissue. These imaging studies help determine the extent of the disease and whether it has spread beyond the breast to nearby lymph nodes or other parts of the body.

The complete pathology report combines all these findings to give you and your healthcare team a comprehensive understanding of your specific breast cancer type. For hormone receptor negative, HER2 positive breast cancer, this means the cancer cells don’t have hormone receptors for estrogen or progesterone, but they do have high levels of HER2. This combination tells your doctors which treatments are most likely to be effective for your particular cancer.^[2]

Results from tissue testing are usually available within one to three weeks after the biopsy or surgery. This waiting period allows the laboratory to perform all necessary tests carefully and accurately. Your healthcare provider will review these results with you and explain what they mean for your treatment plan.^[18]

Diagnostics for Clinical Trial Qualification

When considering participation in a clinical trial for breast cancer, additional or repeated diagnostic tests may be required beyond those performed for standard clinical care. Clinical trials often have strict criteria about which patients can enroll, based on specific characteristics of their cancer. These criteria help researchers ensure that the treatment being studied is appropriate for the participants and that results can be interpreted accurately.

For clinical trials involving hormone receptor negative, HER2 positive breast cancer, verification of both the hormone receptor status and HER2 status is typically mandatory. Some trials may require that your tumor tissue be retested at a central laboratory to confirm the original diagnosis. This retesting ensures consistency across all study participants, as different laboratories may use slightly different methods or interpret results with minor variations.

The same core diagnostic procedures used in routine clinical practice form the foundation for trial eligibility testing. This includes confirmation through immunohistochemistry (IHC) that your cancer has a HER2 score of 3+, or confirmation through specialized testing if the initial score was 2+. The trial protocol will also verify that your cancer lacks hormone receptors, meaning it tested negative for both estrogen and progesterone receptors.^[5]

Beyond biomarker testing, clinical trials often require detailed information about the stage of your cancer. This means confirming tumor size, the number and location of any involved lymph nodes, and whether the cancer has spread to distant organs. Imaging studies such as CT scans, PET scans, or bone scans may be needed to establish this information clearly. These tests help determine whether you meet the trial’s criteria regarding disease extent.^[5]

Many trials also require baseline blood tests to assess your overall health and organ function. These might include tests of your liver and kidney function, blood cell counts, and other markers that help ensure you’re healthy enough to participate safely. Heart function tests, such as an echocardiogram or a measurement of how well your heart pumps blood, may also be required, especially if the trial involves treatments that could affect the heart.

Clinical trials may have specific requirements about the timing of diagnostic tests. For example, some trials require that certain tests be performed within a specific timeframe before you can enroll, such as within 28 days. This ensures that the information about your cancer is current and reflects your situation at the time you begin the trial treatment.

Some research studies may also require additional tissue samples beyond what was collected for your initial diagnosis. This might involve a new biopsy if the original sample is insufficient or if the trial requires fresh tissue rather than stored samples. While this may sound concerning, these additional samples are essential for the research and may provide valuable information about how the treatment is working.

It’s worth noting that participating in clinical trials can sometimes provide access to cutting-edge diagnostic technologies that aren’t yet widely available in routine care. These might include more detailed genetic testing of the tumor or advanced imaging techniques. While the primary purpose of these tests is for research, the information gained may also benefit your care.